Shares of Incyte INCY were on the upward trajectory in the past three months. The stock has risen 19.6% in this time frame compared with the industry’s growth of 8.9%. Last week, Incyte announced that it granted restricted stock unit awards (RSUs), representing an aggregate of 14,577 shares of the company’s common stock, and stock option awards to purchase an aggregate of 18,149 shares of the company’s common stock to 27 new employees. The company’s shares rose following this announcement. Zacks Investment Research Image Source: Zacks Investment Research Incyte made a similar announcement last month, wherein it granted RSUs, representing an aggregate of 14,090 shares of its common stock, and stock option awards to purchase an aggregate of 9,238 shares of the common stock to 17 new employees. INCY’s shares also jumped in May after the company announced a share repurchase authorization of $2.0 billion. Incyte had commenced a modified ‘Dutch Auction’ tender offer to repurchase shares of its common stock for an aggregate price of up to $1.672 billion. The results of the tender offer were announced last month. Incyte accepted 27.8 million shares of its common stock for purchase at a price of $60.00 per share, for a total cost of approximately $1.672 billion, excluding fees and expenses related to the tender offer. These shares represented approximately 12.4% of the company’s total outstanding shares as of Jun 7, 2024. INCY had simultaneously entered into a separate stock purchase agreement with the Baker Entities to repurchase up to $328.0 million of its common stock. In total, Incyte planned to repurchase a total of 33.3 million of its common stock through the tender offer and the stock purchase agreement at a price of $60.00 per share. These shares represented approximately 14.8% of the company’s total shares as of Jun 7, 2024. Investors appreciated the company’s efforts to increase returns for the shareholders. In May, Incyte acquired Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders. The acquisition added EP262 and EP547 to INCY’s portfolio. EP262 is a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2). The candidate is being evaluated to treat multiple mast cell-mediated diseases, including chronic inducible urticaria, chronic spontaneous urticaria and atopic dermatitis. EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus. Incyte is heavily dependent on its lead drug Jakafi for growth, and hence, any effort to diversify the revenue base is positive as Jakafi is slated to lose patent protection toward the end of the decade. Jakafi, a first-in-class JAK1/JAK2 inhibitor, is approved for the treatment of polycythemia vera (PV) and intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF and post-essential thrombocythemia MF. It is also approved for steroid-refractory acute graft versus host disease in adult and pediatric patients aged 12 years or older in the United States. INCY has a collaboration agreement with the Swiss pharma giant Novartis NVS for Jakafi. Notably, Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi outside the country. In February 2024, Incyte entered into an asset purchase agreement with MorphoSys AG. This gave Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed, in the United States (as Monjuvi) and outside the country (as Minjuvi). While the move to buy back shares boosts returns for shareholders, Incyte needs to revamp its business plans and expand its portfolio to maintain momentum. Zacks Rank & Stocks to Consider Incyte currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Entrada Therapeutics TRDA and Corcept Therapeutics CORT, both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Entrada’s loss per share estimate for 2024 has narrowed from 27 cents to 13 cents in the past 60 days. The same for 2025 has narrowed from $3.44 to $3.21 in the past 30 days. In the past 60 days, estimates for CORT’s 2024 earnings per share have improved from 90 to 95 cents. Shares of CORT have rallied 37.8% in the past three months. CORT’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 33.7%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS):Free Stock Analysis Report Incyte Corporation (INCY):Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT):Free Stock Analysis Report Entrada Therapeutics, Inc. (TRDA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...